Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes.
Zhuang L, Chen J, Yu J, Marathe A, Sahajwalla C, Borigini M, Maynard J, Burckart GJ, Wang Y.
Zhuang L, et al.
Clin Pharmacol Ther. 2019 Sep;106(3):557-567. doi: 10.1002/cpt.1302. Epub 2019 Jan 28.
Clin Pharmacol Ther. 2019.
PMID: 30447083
Review.
Canakinumab has been approved to treat patients with cryopyrin-associated periodic syndrome, a periodic fever syndrome, and systemic juvenile systemic arthritis, with age cutoffs of 4 years and 2 years, respectively. In 2016, the US Food and Drug Administrati …
Canakinumab has been approved to treat patients with cryopyrin-associated periodic syndrome, a periodic fever syndrome, …